Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by thewolf4on Nov 15, 2019 6:55pm
220 Views
Post# 30358948

Ryplazim Partnership

Ryplazim PartnershipSection 5.1 of the new SALP loan agreement..

"Consummation of Certain Transactions.
The Borrower hereby acknowledges and confirms that it will use its reasonable best efforts to complete the Prometic Bioseparations Ltd. sale by the Outside Date (as defined in the Share Purchase Agreement) and the Licensing Transaction by [REDACTED – SENSITIVE COMMERCIAL INFORMATION]."

Ryplazim partnership must be pretty certain if SALP is adding it into the loan agreements.
<< Previous
Bullboard Posts
Next >>